CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.875 USD -1.54%
Market Cap: 644.9m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CureVac NV
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Cash from Investing Activities
-€55.2m
CAGR 3-Years
-7%
CAGR 5-Years
-67%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Cash from Investing Activities
-€7B
CAGR 3-Years
-263%
CAGR 5-Years
-154%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Cash from Investing Activities
€46.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Cash from Investing Activities
-€31.4m
CAGR 3-Years
-25%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Cash from Investing Activities
€1.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Cash from Investing Activities
-€17.4m
CAGR 3-Years
-219%
CAGR 5-Years
0%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
645m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.43 USD
Undervaluation 35%
Intrinsic Value
Price

See Also

What is CureVac NV's Cash from Investing Activities?
Cash from Investing Activities
-55.2m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Cash from Investing Activities amounts to -55.2m EUR.

What is CureVac NV's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-67%

Over the last year, the Cash from Investing Activities growth was 41%. The average annual Cash from Investing Activities growth rates for CureVac NV have been -7% over the past three years , -67% over the past five years .

Back to Top